JGL Pharmaceutical hires 85 new workers, secures major investment
Croatian pharmaceutical company Jadran Galenski Laboratorij (JGL) has employed 85 new workers and secured a major investment, despite the challenges of the COVID-19 pandemic.
JGL, which uses bag-on-valve technology, signed a contract with the Croatian Bank for Reconstructed and Development (HBOR) for the Integra 2020 project, valued at HRK 373 million (€49 million), which will enable it to expand in the international market.
The company plans to invest in sterile pharmaceutical production, R&D, a new pilot plant and a robotised logistics-distribution centre. The project is expected to increase capacities for the production of sterile pharmaceutical solutions by 60% and integrate the research and quality process in Rijeka.
According to Total Croatia News, JGL executive Mislav Vucic said he is proud of the results achieved during challenging times, adding that the company would continue with its strategic projects in 2021, investing in its brands, markets, and technology.
Vucic said the pandemic would have a major impact on the economy, but it also pointed out the significance of having a strong industry based on highly sophisticated technology.
“That is why we consider Integra 2020 to be a capital project that will position us even more strongly on the global pharmaceutical map and enable us to produce an additional 41 million sterile sprays, eye drops, and BoV products, intended primarily for export,” said Vucic.
“Thanks to this investment, we are significantly raising the company’s development-technological competencies and its global competitiveness.”
JGL, which uses bag-on-valve technology, signed a contract with the Croatian Bank for Reconstructed and Development (HBOR) for the Integra 2020 project, valued at HRK 373 million (€49 million), which will enable it to expand in the international market.
The company plans to invest in sterile pharmaceutical production, R&D, a new pilot plant and a robotised logistics-distribution centre. The project is expected to increase capacities for the production of sterile pharmaceutical solutions by 60% and integrate the research and quality process in Rijeka.
According to Total Croatia News, JGL executive Mislav Vucic said he is proud of the results achieved during challenging times, adding that the company would continue with its strategic projects in 2021, investing in its brands, markets, and technology.
Vucic said the pandemic would have a major impact on the economy, but it also pointed out the significance of having a strong industry based on highly sophisticated technology.
“That is why we consider Integra 2020 to be a capital project that will position us even more strongly on the global pharmaceutical map and enable us to produce an additional 41 million sterile sprays, eye drops, and BoV products, intended primarily for export,” said Vucic.
“Thanks to this investment, we are significantly raising the company’s development-technological competencies and its global competitiveness.”
